Serving science company Thermo Fisher Scientific revealed on Tuesday the launch of the new AcroMetrix Coronavirus 2019 (COVID-19) RNA Control product to monitor and validate COVID-19 molecular diagnostic tests.

The company has designed and developed this control as a synthetic RNA, non-infectious control to help labs validate and monitor COVID-19 molecular diagnostic tests at two different concentrations: a low positive control and an ultra-low positive control under FDA guidelines.

AcroMetrix Coronavirus 2019 (COVID-19) RNA Control is prepared by formulating synthetic RNA transcripts with highly unique N, S, E and Orf1ab regions of SARS-CoV-2 genome into proprietary buffer. The kit contains two vials of SARS-CoV-2 specific RNA that will result low positive and ultra-low positive in used Polymerase Chain Reaction (PCR) based Coronavirus 2019 nucleic acid testing methods.

Additionally, the company's online resource has up-to-date information about its response to the COVID-19 pandemic, including availability of diagnostic test kits. The COVID-19 RNA Control is available as a Research Use Only (RUO) product and is not intended for clinical use.